Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety.

Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach.
AuthorsJorge Paz Rodriguez, Michael P Murphy, Soonjun Hong, Marialaura Madrigal, Keith L March, Boris Minev, Robert J Harman, Chien-Shing Chen, Ruben Berrocal Timmons, Annette M Marleau, Neil H Riordan
JournalInternational archives of medicine (Int Arch Med) Vol. 5 Pg. 5 ( 2012) ISSN: 1755-7682 [Electronic] England
PMID22313603 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: